Archive


Category: $163M

  • GSK to Acquire 10% stake in CureVac for $163M

    Shots: GSK will invest $163M (€150m) in CureVac for a 10% stake to collaborate for the research, development, manufacturing, and commercialization of up to five mRNA-based vaccines and mAbs targeting infectious disease pathogens excluding CureVac’s existing COVID-19 mRNA and rabies vaccines research programs CureVac to receive $137M (€120m) as upfront, $34.3 (€30m) as one-time reimbursable […]